Central Sterile Corneal Ulceration Medication

  • Author: Saadia Zohra Farooqui, MBBS; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Dec 1, 2011
 

Medication Summary

As discussed in Medical Care, a number of medications for sterile corneal ulcers refractory to conventional treatment are currently being investigated with respect to their clinical efficacy (eg, fibronectin, vitamin A, ascorbic acid, serum-derived tears, metalloproteinase inhibitors, neurotrophic growth factor). Therefore, standard dosing, indications, treatment regimens, and contraindications with respect to these medications are not available. The authors recommend that interested physicians directly contact clinical investigators for specific treatment regimens currently used in treatment trials.

Antibiotics often are used prophylactically in treating patients with sterile corneal ulcerations. Specific dosing and medication information on topical antibiotics are not included in this article.

Immunomodulatory treatment regimens are complex, and elaborating on medication dosing and treatment regimens for specific rheumatologic diseases is beyond the scope of this article.

Next

Ophthalmic corticosteroids

Class Summary

Minimize the activity of inflammatory cells and formation of granulomas. Used in symptomatic patients and commonly provides symptomatic improvement.

View full drug information

Prednisolone ophthalmic (AK-Pred, Pred Forte, Pred Mild, Inflamase Forte) Suspension 0.12%

 

Decreases inflammation and corneal neovascularization. Suppresses migration of polymorphonuclear leukocytes and reverses increased capillary permeability.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Saadia Zohra Farooqui, MBBS  Aga Khan University Medical College, Pakistan

Disclosure: Nothing to disclose.

Coauthor(s)

C Stephen Foster, MD, FACS, FACR, FAAO  Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Founder and President, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution

C Stephen Foster, MD, FACS, FACR, FAAO is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Association of Immunologists, American College of Rheumatology, American College of Surgeons, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, American Uveitis Society, Association for Research in Vision and Ophthalmology, Massachusetts Medical Society, Royal Society of Medicine, and Sigma Xi

Disclosure: Nothing to disclose.

Joseph JK Ma, MD  Assistant Professor, Department of Ophthalmology, University of Toronto Faculty of Medicine, Canada

Joseph JK Ma, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Specialty Editor Board

Fernando H Murillo-Lopez, MD  Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Christopher J Rapuano, MD  Professor, Department of Ophthalmology, Jefferson Medical College of Thomas Jefferson University; Director of the Cornea Service, Co-Director of Refractive Surgery Department, Wills Eye Institute

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery, and Pan-American Association of Ophthalmology

Disclosure: Allergan Honoraria Speaking and teaching; Allergan Consulting fee Consulting; Alcon Honoraria Speaking and teaching; Inspire Honoraria Speaking and teaching; RPS Ownership interest Other; Vistakon Honoraria Speaking and teaching; EyeGate Pharma Consulting; Inspire Consulting fee Consulting; Bausch & Lomb Honoraria Speaking and teaching; Bausch & Lomb Consulting fee Consulting

Ralph Garzia, OD  Assistant Dean for Clinical and Academic Programs, Associate Professor, College of Optometry, University of Missouri at St Louis

Ralph Garzia, OD is a member of the following medical societies: American Academy of Optometry and American Optometric Association

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References

  1. Wentworth JS, Paterson CA, Gray RD. Effect of a metalloproteinase inhibitor on established corneal ulcers after an alkali burn. Invest Ophthalmol Vis Sci. Jun 1992;33(7):2174-9. [Medline].

  2. Gabison EE, Mourah S, Steinfels E, et al. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am J Pathol. Jan 2005;166(1):209-19. [Medline].

  3. Shimmura S, Igarashi R, Yaguchi H, et al. Lecithin-bound superoxide dismutase in the treatment of noninfectious corneal ulcers. Am J Ophthalmol. May 2003;135(5):613-9. [Medline].

  4. Tripathi BK, Stepp MA, Gao CY, et al. The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo. Mol Vis. Mar 17 2008;14:542-9. [Medline].

  5. Sigelman S, Friedenwald JS. Mitotic and wound-healing activities of the corneal epithelium; effect of sensory denervation. AMA Arch Ophthalmol. Jul 1954;52(1):46-57. [Medline].

  6. Nakamura M, Chikama T, Nishida T. Synergistic effect with Phe-Gly-Leu-Met-NH2 of the C-terminal of substance P and insulin-like growth factor-1 on epithelial wound healing of rabbit cornea. Br J Pharmacol. May 1999;127(2):489-97. [Medline].

  7. Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. Jul 2000;107(7):1347-51; discussion 1351-2. [Medline].

  8. Dohlman CH, Slansky HH, Laibson PR, et al. Artificial corneal epithelium in acute alkali burns. Ann Ophthalmol. 1969;112.

  9. Kenyon KR, Berman M, Rose J, et al. Prevention of stromal ulceration in the alkali-burned rabbit cornea by glued-on contact lens. Evidence for the role of polymorphonuclear leukocytes in collagen degradation. Invest Ophthalmol Vis Sci. Jun 1979;18(6):570-87. [Medline].

  10. Nubile M, Dua HS, Lanzini M, Ciancaglini M, Calienno R, Said DG, et al. In vivo analysis of stromal integration of multilayer amniotic membrane transplantation in corneal ulcers. Am J Ophthalmol. May 2011;151(5):809-822.e1. [Medline].

  11. Yoon KC, You IC, Im SK, et al. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology. Sep 2007;114(9):1637-42. [Medline].

  12. Alio JL, Abad M, Artola A, et al. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. Jul 2007;114(7):1286-1293.e1. [Medline].

  13. Saika S, Miyamoto T, Yamanaka O, et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol. May 2005;166(5):1393-403. [Medline].

  14. Sosne G, Qiu P, Christopherson PL, et al. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. Apr 2007;84(4):663-9. [Medline].

  15. Saika S, Yamanaka O, Okada Y, et al. Effect of overexpression of PPARgamma on the healing process of corneal alkali burn in mice. Am J Physiol Cell Physiol. Jul 2007;293(1):C75-86. [Medline].

  16. Ioannidis AS, Zagora SL, Wechsler AW. A non-healing corneal ulcer as the presenting feature of type 1 diabetes mellitus: a case report. J Med Case Reports. Nov 4 2011;5(1):539. [Medline].

  17. Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. 2nd ed. Boston: WB Saunders Co; 2000.

  18. Dua HS, Gomes JA, Singh A. Corneal epithelial wound healing. Br J Ophthalmol. May 1994;78(5):401-8. [Medline].

  19. Geerling G, Joussen AM, Daniels JT, et al. Matrix metalloproteinases in sterile corneal melts. Ann N Y Acad Sci. Jun 30 1999;878:571-4. [Medline].

  20. Gipson IK, Inatomi T. Extracellular matrix and growth factors in corneal wound healing. Curr Opin Ophthalmol. Aug 1995;6(4):3-10. [Medline].

  21. He J, Bazan NG, Bazan HE. Alkali-induced corneal stromal melting prevention by a novel platelet-activating factor receptor antagonist. Arch Ophthalmol. Jan 2006;124(1):70-8. [Medline].

  22. Imanishi J, Kamiyama K, Iguchi I, et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res. Jan 2000;19(1):113-29. [Medline].

  23. Kaufman HE, et al, eds. The Cornea. 2nd ed. Boston: Butterworth-Heinemann; 1998.

  24. Nagano T, Nakamura M, Nakata K, et al. Effects of substance P and IGF-1 in corneal epithelial barrier function and wound healing in a rat model of neurotrophic keratopathy. Invest Ophthalmol Vis Sci. Sep 2003;44(9):3810-5. [Medline].

  25. Watanabe M, Yano W, Kondo S, et al. Up-regulation of urokinase-type plasminogen activator in corneal epithelial cells induced by wounding. Invest Ophthalmol Vis Sci. Aug 2003;44(8):3332-8. [Medline].

  26. Wilson SE, Liu JJ, Mohan RR. Stromal-epithelial interactions in the cornea. Prog Retin Eye Res. May 1999;18(3):293-309. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.